Avidity Biosciences Inc
NASDAQ:RNA 1:14:46 PM EDT
| Market Cap (Intraday) | 5.53B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $45.86 |
| 50-Day MA | $43.88 |
| 200-Day MA | $30.12 |
Avidity Biosciences Inc Stock, NASDAQ:RNA
10578 Science Center Drive, Suite 125, San Diego, California 92121
United States of America
Phone: +1.858.401.7900
Number of Employees: 253
Description
Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.